Anti-MAG neuropathy refers to a rare auto-immune associated cause of peripheral neuropathy (PN). In this case, the person’s own immune system (specifically, the IgM monoclonal antibodies) attack nerve cells required for a healthy peripheral nervous system –resulting in a slowly progressive and debilitating condition. Patients often experience loss of mobility, muscle weakness, balance, numbness and pain in varying degrees.

Three neurologists recently published an outstanding review of this condition which is estimated to affect only 7/100,000 PN patients. Anti–Myelin-Associated Glycoprotein Neuropathy: Where Do We Stand? Published in Muscle and Nerve (Wiley, 22, July 2023).

Anti–Myelin-Associated Glycoprotein Neuropathy: Where Do We Stand?

In the paper, Drs. Amro Stino (University of Michigan), Jeffrey Allen (University of Minnesota), and Bakri Elsheikh (The Ohio State University) undertake a comprehensive review of Anti-MAG PN, including the diagnosis, clinicometrics, biometrics and treatment of this condition. In the course of their review, they summarize the varied results of two controlled trials of rituximab and discuss the current state of immunotherapeutic research.  

The authors conclude that “[t]here is an urgent need for improved clinicometrics, biomarkers, and therapeutics in anti-MAG neuropathy.” They note that the ongoing IMAGiNe study – currently funded in part by the Foundation for Peripheral Neuropathy – should help provide a path forward in clinical trials and practice. It is hoped that, going forward, this study will help neurologists and anti-MAG patients meet the challenges they face.

Leave a Comment